Acrivon Therapeutics (ACRV) News Today $5.54 -0.31 (-5.30%) Closing price 02/21/2025 04:00 PM EasternExtended Trading$5.66 +0.12 (+2.08%) As of 02/21/2025 07:05 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 Time Period Analysts Set Acrivon Therapeutics, Inc. (NASDAQ:ACRV) Price Target at $23.67February 19 at 4:05 AM | americanbankingnews.comAcrivon Therapeutics, Inc. (NASDAQ:ACRV) Short Interest Down 6.0% in JanuaryFebruary 19 at 2:36 AM | americanbankingnews.comAcrivon Therapeutics, Inc. (NASDAQ:ACRV) Short Interest UpdateAcrivon Therapeutics, Inc. (NASDAQ:ACRV - Get Free Report) saw a significant drop in short interest in the month of January. As of January 31st, there was short interest totalling 1,100,000 shares, a drop of 6.0% from the January 15th total of 1,170,000 shares. Based on an average daily volume of 60,300 shares, the days-to-cover ratio is presently 18.2 days. Currently, 5.0% of the company's stock are sold short.February 18, 2025 | marketbeat.comAcrivon Therapeutics, Inc. (NASDAQ:ACRV) Given Average Recommendation of "Buy" by AnalystsAcrivon Therapeutics, Inc. (NASDAQ:ACRV - Get Free Report) has been assigned a consensus rating of "Buy" from the eight analysts that are currently covering the stock, MarketBeat Ratings reports. Eight research analysts have rated the stock with a buy recommendation. The average 12-month price objFebruary 14, 2025 | marketbeat.comAcrivon Therapeutics announces FDA granted BDD for ACR-368February 6, 2025 | markets.businessinsider.comAcrivon Therapeutics Stock Rises 14% On FDA Recognition For ACR-368 OncoSignature AssayFebruary 5, 2025 | markets.businessinsider.comAcrivon Therapeutics (ACRV): AI-Powered Precision Oncology Gets FDA Breakthrough StatusFebruary 5, 2025 | msn.comAcrivon Therapeutics Gets FDA Breakthrough Device Designation for Cancer IdentificationFebruary 5, 2025 | marketwatch.comACR-368 OncoSignature assay gains FDA breakthrough statusFebruary 5, 2025 | msn.comAcrivon Therapeutics:FDA Grants Breakthrough Device Designation For ACR-368 OncoSignature AssayFebruary 5, 2025 | markets.businessinsider.comAcrivon Therapeutics Announces FDA has Granted Breakthrough Device Designation for ACR-368 OncoSignature Assay for Endometrial CancerFebruary 5, 2025 | finance.yahoo.comBrokers Offer Predictions for ACRV FY2024 EarningsAcrivon Therapeutics, Inc. (NASDAQ:ACRV - Free Report) - Analysts at Cantor Fitzgerald issued their FY2024 earnings per share estimates for Acrivon Therapeutics in a report released on Monday, February 3rd. Cantor Fitzgerald analyst L. Watsek expects that the company will earn ($2.42) per share fFebruary 5, 2025 | marketbeat.comCantor Fitzgerald Initiates Coverage of Acrivon Therapeutics (ACRV) with Overweight RecommendationFebruary 1, 2025 | msn.comCantor Fitzgerald sets Acrivon stock to Overweight on AP3 platformJanuary 31, 2025 | msn.comAcrivon Therapeutics initiated with an Overweight at Cantor FitzgeraldJanuary 31, 2025 | markets.businessinsider.comAcrivon Therapeutics, Inc. (ACRV) Initiated with a Buy at Cantor FitzgeraldJanuary 31, 2025 | markets.businessinsider.comCantor Fitzgerald Initiates Coverage on Acrivon Therapeutics (NASDAQ:ACRV)Cantor Fitzgerald initiated coverage on Acrivon Therapeutics in a report on Friday. They set an "overweight" rating for the company.January 31, 2025 | marketbeat.comAcrivon Therapeutics (NASDAQ:ACRV) Now Covered by Analysts at KeyCorpKeyCorp began coverage on Acrivon Therapeutics in a research note on Friday. They issued an "overweight" rating for the company.January 31, 2025 | marketbeat.comAcrivon Therapeutics, Inc. (NASDAQ:ACRV) Receives Consensus Rating of "Buy" from AnalystsShares of Acrivon Therapeutics, Inc. (NASDAQ:ACRV - Get Free Report) have been assigned an average rating of "Buy" from the six research firms that are currently covering the company, MarketBeat Ratings reports. Six analysts have rated the stock with a buy recommendation. The average 1 year priceJanuary 20, 2025 | marketbeat.comShort Interest in Acrivon Therapeutics, Inc. (NASDAQ:ACRV) Increases By 6.3%Acrivon Therapeutics, Inc. (NASDAQ:ACRV - Get Free Report) was the recipient of a large increase in short interest during the month of December. As of December 31st, there was short interest totalling 1,180,000 shares, an increase of 6.3% from the December 15th total of 1,110,000 shares. Based on an average daily trading volume, of 56,600 shares, the short-interest ratio is currently 20.8 days. Currently, 5.4% of the company's stock are sold short.January 19, 2025 | marketbeat.comAcrivon Therapeutics, Inc. (NASDAQ:ACRV) Receives Consensus Rating of "Buy" from BrokeragesShares of Acrivon Therapeutics, Inc. (NASDAQ:ACRV - Get Free Report) have received an average rating of "Buy" from the six analysts that are covering the firm, Marketbeat Ratings reports. Six research analysts have rated the stock with a buy recommendation. The average 1-year price target among brDecember 26, 2024 | marketbeat.comAcrivon Therapeutics: Endometrial Cancer Data Continues To Justify A Nascent ThesisDecember 12, 2024 | seekingalpha.comAcrivon Therapeutics, Inc. (NASDAQ:ACRV) Receives Average Rating of "Buy" from BrokeragesAcrivon Therapeutics, Inc. (NASDAQ:ACRV - Get Free Report) has been given an average recommendation of "Buy" by the six research firms that are currently covering the company, Marketbeat reports. Six research analysts have rated the stock with a buy rating. The average 1-year target price among brDecember 1, 2024 | marketbeat.comEquities Analysts Offer Predictions for ACRV FY2024 EarningsAcrivon Therapeutics, Inc. (NASDAQ:ACRV - Free Report) - Research analysts at HC Wainwright dropped their FY2024 EPS estimates for shares of Acrivon Therapeutics in a research report issued on Wednesday, November 13th. HC Wainwright analyst E. Bodnar now expects that the company will post earningNovember 18, 2024 | marketbeat.comAcrivon Therapeutics Reports Promising Clinical Progress and Financial ResultsNovember 15, 2024 | markets.businessinsider.comAcrivon Therapeutics: Promising Clinical Data and Strategic Progress Justify Buy RatingNovember 14, 2024 | markets.businessinsider.comStrong Growth Outlook for Acrivon Therapeutics, Inc. Backed by Promising Pipeline and Strategic AdvancementsNovember 14, 2024 | markets.businessinsider.comAcrivon Therapeutics Reports Third Quarter 2024 Financial Results and Business HighlightsNovember 14, 2024 | finance.yahoo.comPromising Clinical Developments and Strong Financial Position Drive Buy Rating for Acrivon TherapeuticsNovember 14, 2024 | markets.businessinsider.comAcrivon Therapeutics: Promising Pipeline and Robust Financials Underpin Buy RatingNovember 14, 2024 | markets.businessinsider.comAcrivon Therapeutics (NASDAQ:ACRV) Price Target Cut to $27.00 by Analysts at BMO Capital MarketsBMO Capital Markets cut their price objective on shares of Acrivon Therapeutics from $28.00 to $27.00 and set an "outperform" rating on the stock in a report on Thursday.November 14, 2024 | marketbeat.comAcrivon Therapeutics (NASDAQ:ACRV) Given Buy Rating at HC WainwrightHC Wainwright restated a "buy" rating and set a $22.00 target price on shares of Acrivon Therapeutics in a report on Thursday.November 14, 2024 | marketbeat.comAcrivon Therapeutics, Inc. (NASDAQ:ACRV) Receives Consensus Recommendation of "Buy" from AnalystsAcrivon Therapeutics, Inc. (NASDAQ:ACRV - Get Free Report) has earned an average recommendation of "Buy" from the six analysts that are covering the stock, Marketbeat Ratings reports. Six analysts have rated the stock with a buy rating. The average 12-month target price among brokerages that haveNovember 6, 2024 | marketbeat.comAcrivon Therapeutics: Promising Innovations in WEE1/PKMYT1 Inhibition and AP3 Platform Drive Buy RatingOctober 29, 2024 | markets.businessinsider.comAcrivon Therapeutics: Buy Rating Driven by Promising Oncology Advancements and Strategic PositioningOctober 29, 2024 | markets.businessinsider.comAcrivon Therapeutics, Inc. (NASDAQ:ACRV) Short Interest Down 5.5% in SeptemberAcrivon Therapeutics, Inc. (NASDAQ:ACRV - Get Free Report) was the target of a large drop in short interest in the month of September. As of September 30th, there was short interest totalling 1,210,000 shares, a drop of 5.5% from the September 15th total of 1,280,000 shares. Based on an average trading volume of 93,600 shares, the days-to-cover ratio is presently 12.9 days. Currently, 5.6% of the company's stock are sold short.October 17, 2024 | marketbeat.comAcrivon Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)October 16, 2024 | globenewswire.comAcrivon Therapeutics Launches Phase 1 Cancer Trial, Advances Oncology PipelineOctober 12, 2024 | finance.yahoo.comAcrivon Therapeutics Announces Initial Patient Dosing in Phase 1 Trial of ACR-2316, a Novel WEE1/PKMYT1 Inhibitor Designed Using AP3 for Superior Single-Agent ActivityOctober 11, 2024 | globenewswire.comAcrivon Therapeutics (NASDAQ:ACRV) Stock, Short Interest ReportOctober 7, 2024 | benzinga.comMarshall Wace LLP Raises Stock Holdings in Acrivon Therapeutics, Inc. (NASDAQ:ACRV)Marshall Wace LLP lifted its holdings in shares of Acrivon Therapeutics, Inc. (NASDAQ:ACRV - Free Report) by 58.8% in the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 948,866 shares of the company's stock afOctober 2, 2024 | marketbeat.comPerceptive Advisors LLC Has $31.09 Million Stock Position in Acrivon Therapeutics, Inc. (NASDAQ:ACRV)Perceptive Advisors LLC lifted its position in shares of Acrivon Therapeutics, Inc. (NASDAQ:ACRV - Free Report) by 78.2% in the second quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 5,360,858 shares of the company's stocSeptember 30, 2024 | marketbeat.comAcrivon Therapeutics, Inc. (NASDAQ:ACRV) Short Interest Up 24.3% in SeptemberAcrivon Therapeutics, Inc. (NASDAQ:ACRV - Get Free Report) was the recipient of a large growth in short interest in September. As of September 15th, there was short interest totalling 1,280,000 shares, a growth of 24.3% from the August 31st total of 1,030,000 shares. Currently, 5.9% of the company's shares are short sold. Based on an average daily volume of 101,600 shares, the days-to-cover ratio is currently 12.6 days.September 28, 2024 | marketbeat.comAcrivon Therapeutics, Inc. (NASDAQ:ACRV) Position Raised by Sands Capital Ventures LLCSands Capital Ventures LLC grew its position in shares of Acrivon Therapeutics, Inc. (NASDAQ:ACRV - Free Report) by 28.4% in the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 2,122,605 shares of tSeptember 21, 2024 | marketbeat.comAcrivon shares maintain buy rating on positive analyst ratingSeptember 18, 2024 | uk.investing.comAcrivon Therapeutics maintains Buy rating from H.C. Wainwright with steady price targetSeptember 18, 2024 | uk.investing.comBreaking Down Acrivon: Deep Dive Into Revenue, Profitability, And ProspectsSeptember 18, 2024 | seekingalpha.comAcrivon Therapeutics: Buy Rating Justified by Promising Clinical Data and Strategic Research InitiativesSeptember 18, 2024 | markets.businessinsider.comLadenburg Thalmann Upgrades Acrivon Therapeutics (ACRV)September 17, 2024 | msn.comTD Cowen Remains a Buy on Acrivon Therapeutics, Inc. (ACRV)September 17, 2024 | markets.businessinsider.com Get Acrivon Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ACRV and its competitors with MarketBeat's FREE daily newsletter. Email Address ACRV Media Mentions By Week ACRV Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. ACRV News Sentiment▼0.990.60▲Average Medical News Sentiment ACRV News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. ACRV Articles This Week▼42▲ACRV Articles Average Week Get Acrivon Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ACRV and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Relay Therapeutics News Today Tyra Biosciences News Today AnaptysBio News Today Kura Oncology News Today CorMedix News Today Arbutus Biopharma News Today Pharming Group News Today Immatics News Today ORIC Pharmaceuticals News Today Rapport Therapeutics News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:ACRV) was last updated on 2/22/2025 by MarketBeat.com Staff From Our PartnersSecret financial plot unfolding in Washington DC… [DEVELOPING]What stocks are next up to soar in 2025? I believe I’ve found the answer - and it might surprise you. Yo...Timothy Sykes | Sponsored[RFK Jr CONFIRMED] Here’s why Dems are TERRIFIEDRobert F. Kennedy Jr was just confirmed as Trump’s secretary of Health and Human Services… but it was NOT easy...NewMarket Health Publishing, LLC. | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredElon Takes Aim at Social SecurityElon Musk just dropped another bombshell... He revealed his DOGE organization has been taking aim at Social...Altimetry | SponsoredNvidia’s Next Big Move Comes on Feb. 26Nvidia isn't the only company that benefits greatly from these earnings calls. That's because a handful of ...Weiss Ratings | SponsoredHow to trade Executive Order 14154Trump’s pen must be running out of ink… Since he returned to office he’s signed more than 50 Executive Orde...Porter & Company | SponsoredMajor AI announcement for 2025BIG NEWS: “Market Wizard” Larry Benedict Releases a Whole New Way to Trade AI StocksBrownstone Research | SponsoredHas Trump finally met his match?A new Chinese AI software called "DeepSeek" is sending shockwaves through the market. It's advanced enough ...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Acrivon Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Acrivon Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
